ADHD in Queensland general practice: regulatory update, adult diagnosis and two cases
HealthCert GP update webinar focused on Queensland legislation changes for adult ADHD — how GPs diagnose and manage, stimulant and non-stimulant options, and contrasting cases (Adam declines stimulants; Barbara thrives on Vyvanse). Distinct from earlier allcpd ADHD medicines / assessment pages.
- Clinical presenter
- Dr Simone Gonzo — GP, Caboolture (north of Brisbane / Gubbi Gubbi country). Former registered nurse; University of Queensland medical graduate; mental health, chronic disease and complex primary care; GP registrar / medical student educator; Master of Healthcare Leadership candidate.
- Host
- Campbell — education advisor, HealthCert Education (HealthCert GP update series).
- Session context
- Otter id
R-8dRF0J_IRCgqOEKIhTJBS1O8g· title ADHD Management Webinar · ~64.2 min (3849 s) · recorded 2026-02-18. Main focus: adults under updated Queensland rules, with paediatric contrast. ASR garbles drug names (dexamphetamine, Ritalin, Vyvanse, atomoxetine/Strattera, guanfacine/Intuniv, clonidine) and guideline acronyms (e.g. AADPA) — verify against Queensland Health and current product information. Not a substitute for checking live prescribing legislation.
Key messages for Queensland GPs
- This webinar is about Queensland regulatory change enabling GPs in adult ADHD diagnosis/management — especially vs the old requirement for a recent psychiatrist treatment plan with every prescribing approval.
- ~1 million Australians with ADHD cited; 60–80% of childhood ADHD continues into adulthood; rising recognition (especially women) ≠ necessarily rising true prevalence.
- Diagnosis is clinical and time-consuming (often 2–3 hours shared across GP / psychology / psychiatry / paediatrics; out-of-pocket costs up to ~$2,500 cited in some areas) — not a five-minute label; no blood test.
- DSM-5: symptoms before age 12, ≥6 months, ≥2 settings, not better explained by another condition; adults ≥17 need 5/9 inattentive or hyperactive-impulsive items (children 6/9).
- Medicines: first-line stimulants (methylphenidate, dexamphetamine); short-acting often useful to trial response; long-acting for adherence. Non-stimulants: atomoxetine, guanfacine; also clonidine / some antidepressants as adjuncts. Complex combinations → consider psychiatrist.
- Not everyone wants or tolerates stimulants (Adam) — non-pharmacological care still counts. Others transform (Barbara).
Why more ADHD diagnoses now?
Dr Gonzo framed higher diagnosis rates as mainly awareness and cognitive demand of modern life, better recognition in women, evolving criteria, and improved access to psychologists / mental health nurses — diagnostic growth rather than a sudden explosion in true prevalence. ADHD remains under-recognised and undertreated in Australia; early treatment affects education, relationships, jobs and health.
Pathway: recognition → screening/assessment → confident diagnosis → psychoeducation/support → individualised holistic plan (medicine is only one pillar) → long-term follow-up → advocacy letters for school/work.
Differential symptoms overlap: hyperthyroidism, BPD, PTSD, intellectual impairment, autism, mood/anxiety/personality disorders. Strengths framing: hyperfocus, novel ideas, adventurousness (vs impulsivity) — Einstein, Walt Disney, Jamie Oliver, Simone Biles cited culturally.
Diagnosing adult ADHD
Needs clear functional interference in social/school/work life; onset before 12; not exclusively during psychosis or better explained elsewhere. Full clinical and psychosocial assessment — domains, severity, functional impact, onset story (“always losing football boots / couldn’t sit still at school”).
| Domain | Talk framing |
|---|---|
| Subtypes (DSM-5) | Inattentive; hyperactive-impulsive; combined — many adults blend; hard to assign one box |
| Symptom counts | Children: 6/9; age ≥17: 5/9 in the relevant list |
| Inattentive clues | Sustain attention, listen, finish tasks, organise, avoid sustained mental effort (year 1 reading), lose things, distractible, forgetful |
| Hyperactive-impulsive | Fidgety, on the go, talking/blurting, can’t wait turn, interrupt |
| Who helps | Psychologists, psychiatrists, paediatricians; MHCP + comprehensive referral; help the patient gather collateral (organisation is the illness) |
| Time / cost (Qld shared experience) | ~2–3 hours total, split sessions; up to ~$2,500 out of pocket in some areas; hard in pure bulk-billing settings |
If you have known the person through childhood/adolescence, you may already “know” the trajectory — historically Queensland adult treatment often waited on psychiatrist/paediatrician diagnosis before access.
Diagnostic challenges and disappointment
Some patients believe an ADHD label will fix everything. Dr Gonzo described a patient who paid substantially for psychiatry convinced ADHD was the whole problem — psychiatrist (who knew her) concluded personality disorder with anxiety, not ADHD. Working through grief and alternative therapies took GP + psychologist time. Ask early: “How will you feel if this is not the answer?” Shop-around behaviour for a desired label costs money and may still not help.
Treatment: non-drug and medicines
Individualised plans: severity, strengths, co-occurring depression/anxiety, preferences, life stage (deadlines, new career). Share-care with psychiatry/paediatrics/OT. Non-pharmacological: sleep hygiene, meals, exercise; parent/caregiver training; CBT via psychology; ADHD coaching; reputable online tips; GP Chronic Condition Management Plan → OT; Mental Health Care Plan → psychology.
Pharmacological (adults — as presented)
- First-line stimulants: methylphenidate, dexamphetamine. Short-acting useful to confirm response (wears off quickly); many then prefer once-daily long-acting for lifestyle and fewer missed doses. PBS vs private cost matters.
- Non-stimulants: atomoxetine (Strattera), guanfacine (Intuniv) — if stimulants contraindicated (e.g. some cardiac), not tolerated, or separate trials of both stimulants fail. Sometimes combined with stimulants under experienced care; complex → psychiatrist preferred.
- Other options discussed: clonidine (sleep/settling; lowers BP); some antidepressants helping focus; occasional mention of lamotrigine and other agents as augmenters (ASR unclear — verify).
- ECG: not routinely required before stimulants/atomoxetine unless cardiac features (congenital heart disease, surgery, family history, SOB, etc.). Example: 55-year-old diabetic post-MI with stent — cleared by cardiology, low-dose Ritalin, meaningful benefit.
Queensland regulatory / prescribing update
ASR of the “who can prescribe which age group” table is incomplete. Core narrative from the talk: new Queensland legislation has opened adult ADHD space for GPs (discussion of 18–24 and older age bands, fellowship vs non-fellowship medical practitioners, hospital registrars in specialty context). Previously, Queensland prescribing approvals typically required a psychiatrist treatment plan and recent psychiatrist contact (within ~2–3 years) — widely experienced as difficult. Confirm current Queensland Health / Poisons and Medicines requirements before changing practice.
References pointed to Queensland Health stimulant guidance and Australasian ADHD Professional Association (AADPA — ASR “aacpa”) regulations. Q&A noted pathways are not strictly linear versus guideline diagrams — patients often self-present with symptom lists or school reports.
Case: Adam (25) — stimulant not the answer
Known patient; ADHD diagnosed age 9; childhood stimulants disliked. Bright, average Year 12, many jobs, now adult apprenticeship + partner + one child. Thrill-seeking (motorbikes), restless, poor reading/theory, excellent practical skills, life-of-the-party humour, challenges authority but respects medical opinion, sleeps little without seeking hypnotics, almost no social-media scrolling.
Trial of dexamphetamine for six weeks: he stopped — felt “not himself”, lost wit/energy, tired and sluggish. Preferred non-pharmacological strategies / psychology; workplace already accommodated him. Finished apprenticeship without restarting stimulant. Take-home: meeting criteria does not oblige lifelong stimulants; patient preference and identity matter.
Case: Barbara (67) — Vyvanse life-changing
Midwife / RN transitioning to part-time; long-term psychiatrist for work-related trauma, PTSD, anxiety, depression (already on a long-term psychiatric medicine — ASR unclear; do not invent the drug name). Hard to engage psychology; fast thinker; hyper-research rabbit holes; organised notebooks; U3A learner; peers “can’t keep up”; healthy lifestyle.
Psychiatrist and patient agreed ADHD criteria; trial of Vyvanse (lisdexamfetamine): “better than she’s ever been” — more approachable, patient with children and colleagues, better concentration, less tired, moved into mentoring. Ongoing plan: continue medicine; psychology more self-directed given lifestyle strengths already in place. Resources: reputable Facebook education bites, ADHD Foundation Australia, Queensland Health references.
Q&A highlights
- Duration of stimulants: no fixed upper limit; safe use into 60s discussed with comorbidity specialist input; natural review points at life transitions or patient-led breaks.
- Choosing a stimulant: start with what you know — often short-acting dexamphetamine or Ritalin morning ± midday so evenings are clear; if intolerant or incomplete, consider non-stimulants or long-acting formulations.
- HealthCert promoting a new case-based ADHD short course and an MBS Case Management Essentials course (host plug).